Bioxyne fails in PhIIb with COPD drug, hopes for subset rescue from under-65s
This article was originally published in Scrip
Executive Summary
Australian immunotherapeutics business Bioxyne is pinning its hopes the on the continued development of its immunotherapeutic, HI 164 OV for chronic obstructive pulmonary disease (COPD) in a specific subset of patients after a Phase IIb trial, study HI H005, failed to show a significant benefit of the treatment across the whole study group.